Pharmaceutical Drug Delivery Market Size & Share 2023 to 2032
Market Size by Route Of Administration (Oral, Injectable, Self-Injectors, Topical, Pulmonary, Nasal, Transmucosal), by Application, Facility Of Use (Hospitals, Clinics, Home Care Settings.
Report ID: GMI5565
|
Published Date: April 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Pharmaceutical Drug Delivery Market Size
Pharmaceutical Drug Delivery Market size was more than USD 1.6 trillion in 2022 and is forecast to observe more than 7% CAGR from 2023 to 2032. The rising adoption of self-administration and home care will influence the market development.
Pharmaceutical Drug Delivery Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Emerging preferences for self-administration and at-home care will influence the market trends. A large portion of the elderly population is preferring home care over hospital care as it is a more affordable and practical option. The high prevalence of many diseases and an increase in the number of diabetic patients worldwide has resulted in the widespread usage of self-injector devices for the administration of insulin. As patients are choosing self-administration devices to eliminate the high costs of hospitalization and caregivers, many companies are launching new drug delivery products to meet the impending demand. For instance, in May 2022, Jabil Healthcare launched the Qfinity Autoinjector Platform which is a reusable drug delivery device.
Concerns over needlestick injuries could hamper the growth of the pharmaceutical drug delivery market. Injuries from needlesticks happen when a needle inadvertently pierces the skin. Such wounds are dangerous because they can spread bacteria that can result in deadly bloodborne diseases. As per estimates, around 600,000 to 800,000 needlestick injuries are recorded in the US each year. Healthcare workers are at high risk of needlestick injuries which can lead to serious or fatal infections.
Pharmaceutical Drug Delivery Market Analysis
Pharmaceutical drug delivery market share from the injectable segment is expected to witness a 7.4% CAGR from 2023 to 2032. There are two types of injectable drug delivery systems: traditional and self-injecting. These devices have gained popularity during the COVID-19 pandemic for making vaccines and is continued to be used to treat conditions like diabetes, cancer, and cardiovascular disease. With the rising number of chronic diseases, the demand for these products will increase worldwide. Pharmaceutical companies are actively expanding their manufacturing capacity to boost the production of injectable drug delivery products. For instance, in October 2022, Eisai launched a new injectable drug delivery facility worth USD 69 million. The company built a research building for the development of new products in the segment.
Pharmaceutical drug delivery market share from the infectious diseases segment is predicted to reach more than USD 555 billion by 2032. Worldwide, the prevalence of infectious diseases including SARS, swine flu, TB, and others is rising. Oral or injectable drug delivery techniques are majorly used for the effective treatment of infectious disorders. Climate change and viruses like COVID-19 are increasing the burden of healthcare infrastructure, driving the need for effective drug delivery solutions. As per the CDC, the West Nile virus, Lyme disease, and valley fever are a few examples of infectious diseases that have spread over the years.
Pharmaceutical drug delivery market share from the hospitals segment is expected to reach over USD 1.8 trillion by 2032. This growth will be accelerated by the large patient population visiting hospitals for a range of diseases. Hospitals also provide a wide range of medical services to patients, which accelerates market growth. The advanced infrastructure and medical devices present in hospitals attract more patients. The development of cutting-edge technologies and the presence of highly skilled professionals will influence market growth over the coming years.
North America pharmaceutical drug delivery market share was nearly 49% in 2022. Alcohol consumption, smoking, and sedentary behavior are all contributing to an increase in cases of diseases, which will support market expansion. Additionally, the region is home to a significant number of well-known pharmaceutical brands. Multiple hospitals and other healthcare facilities are in abundance in the region. Furthermore, high healthcare expenditures and expanding government initiatives to support improvement in healthcare sector is expected to endorse pharmaceutical drug delivery companies in the region.
Pharmaceutical Drug Delivery Market Share
are some of the key players in the global pharmaceutical drug delivery market. Initiatives by the companies like partnerships, collaborations, and new product launches are expected to increase market growth over the years. For instance, in March 2023, Sanofi reduced the cost of their popular insulin Lantus by 78% with a cap of USD 35 in order to make the out-of-pocket drugs more affordable for all patients with commercial insurance.
The pharmaceutical drug delivery market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Route of Administration
By Application
By Facility of Use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →